- Home
- MGIH vs NRXS Comparison
MGIH vs NRXS Comparison
Compare MGIH & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- NRXS
- Stock Information
- Founded
- MGIH 1978
- NRXS 2011
- Country
- MGIH Hong Kong
- NRXS United States
- Employees
- MGIH N/A
- NRXS N/A
- Industry
- MGIH Publishing
- NRXS
- Sector
- MGIH Consumer Discretionary
- NRXS
- Exchange
- MGIH Nasdaq
- NRXS Nasdaq
- Market Cap
- MGIH 20.5M
- NRXS 17.8M
- IPO Year
- MGIH 2023
- NRXS 2023
- Fundamental
- Price
- MGIH $1.67
- NRXS $2.31
- Analyst Decision
- MGIH
- NRXS
- Analyst Count
- MGIH 0
- NRXS 0
- Target Price
- MGIH N/A
- NRXS N/A
- AVG Volume (30 Days)
- MGIH 55.0K
- NRXS 22.4K
- Earning Date
- MGIH 10-30-2024
- NRXS 04-08-2025
- Dividend Yield
- MGIH N/A
- NRXS N/A
- EPS Growth
- MGIH N/A
- NRXS N/A
- EPS
- MGIH N/A
- NRXS N/A
- Revenue
- MGIH $38,530,773.00
- NRXS $2,456,219.00
- Revenue This Year
- MGIH N/A
- NRXS $383.16
- Revenue Next Year
- MGIH N/A
- NRXS N/A
- P/E Ratio
- MGIH N/A
- NRXS N/A
- Revenue Growth
- MGIH N/A
- NRXS N/A
- 52 Week Low
- MGIH $1.19
- NRXS $2.05
- 52 Week High
- MGIH $6.83
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- MGIH 50.94
- NRXS 38.24
- Support Level
- MGIH $1.47
- NRXS $2.39
- Resistance Level
- MGIH $1.64
- NRXS $2.51
- Average True Range (ATR)
- MGIH 0.21
- NRXS 0.15
- MACD
- MGIH -0.01
- NRXS -0.03
- Stochastic Oscillator
- MGIH 29.85
- NRXS 7.14
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).